Alexander Gillis
Low intrinsic efficacy for G protein activation can explain the improved side-effect profile of new opioid agonists
Gillis, Alexander; Gondin, Arisbel B.; Kliewer, Andrea; Sanchez, Julie; Lim, Herman D.; Alamein, Claudia; Manandhar, Pradeep; Santiago, Marina; Fritzwanker, Sebastian; Schmidel, Frank; Katte, Timothy A.; Reekie, Tristan; Grimsey, Natasha L.; Kassiou, Michael; Kellam, Barrie; Krasel, Cornelius; Halls, Michelle L.; Connor, Mark; Lane, J. Robert; Schulz, Stefan; Christie, Macdonald J.; Canals, Meritxell
Authors
Arisbel B. Gondin
Andrea Kliewer
Dr JULIE SANCHEZ JULIE.SANCHEZ@NOTTINGHAM.AC.UK
Nottingham Research and Anne McLarenFellowships (School of Pharmacy)
Herman D. Lim
Claudia Alamein
Pradeep Manandhar
Marina Santiago
Sebastian Fritzwanker
Frank Schmidel
Timothy A. Katte
Tristan Reekie
Natasha L. Grimsey
Michael Kassiou
Professor BARRIE KELLAM BARRIE.KELLAM@NOTTINGHAM.AC.UK
PROFESSOR OF MEDICINAL CHEMISTRY
Cornelius Krasel
Michelle L. Halls
Mark Connor
Dr ROB LANE ROB.LANE@NOTTINGHAM.AC.UK
ASSOCIATE PROFESSOR
Stefan Schulz
Macdonald J. Christie
Professor MERITXELL CANALS M.CANALS@NOTTINGHAM.AC.UK
PROFESSOR OF CELLULAR PHARMACOLOGY
Abstract
Biased agonism at G protein–coupled receptors describes the phenomenon whereby some drugs can activate some downstream signaling activities to the relative exclusion of others. Descriptions of biased agonism focusing on the differential engagement of G proteins versus β-arrestins are commonly limited by the small response windows obtained in pathways that are not amplified or are less effectively coupled to receptor engagement, such as β-arrestin recruitment. At the μ-opioid receptor (MOR), G protein–biased ligands have been proposed to induce less constipation and respiratory depressant side effects than opioids commonly used to treat pain. However, it is unclear whether these improved safety profiles are due to a reduction in β-arrestin–mediated signaling or, alternatively, to their low intrinsic efficacy in all signaling pathways. Here, we systematically evaluated the most recent and promising MOR-biased ligands and assessed their pharmacological profile against existing opioid analgesics in assays not confounded by limited signal windows. We found that oliceridine, PZM21, and SR-17018 had low intrinsic efficacy. We also demonstrated a strong correlation between measures of efficacy for receptor activation, G protein coupling, and β-arrestin recruitment for all tested ligands. By measuring the antinociceptive and respiratory depressant effects of these ligands, we showed that the low intrinsic efficacy of opioid ligands can explain an improved side effect profile. Our results suggest a possible alternative mechanism underlying the improved therapeutic windows described for new opioid ligands, which should be taken into account for future descriptions of ligand action at this important therapeutic target.
Citation
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmidel, F., Katte, T. A., Reekie, T., Grimsey, N. L., Kassiou, M., Kellam, B., Krasel, C., Halls, M. L., Connor, M., Lane, J. R., Schulz, S., …Canals, M. (2020). Low intrinsic efficacy for G protein activation can explain the improved side-effect profile of new opioid agonists. Science Signaling, 13(625), Article eaaz3140. https://doi.org/10.1126/scisignal.aaz3140
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 6, 2020 |
Online Publication Date | Mar 31, 2020 |
Publication Date | Mar 31, 2020 |
Deposit Date | Mar 23, 2020 |
Publicly Available Date | Mar 31, 2020 |
Journal | Science Signaling |
Print ISSN | 1945-0877 |
Electronic ISSN | 1937-9145 |
Publisher | American Association for the Advancement of Science |
Peer Reviewed | Peer Reviewed |
Volume | 13 |
Issue | 625 |
Article Number | eaaz3140 |
DOI | https://doi.org/10.1126/scisignal.aaz3140 |
Keywords | Cell Biology; Biochemistry; Molecular Biology |
Public URL | https://nottingham-repository.worktribe.com/output/4193457 |
Publisher URL | https://stke.sciencemag.org/content/13/625/eaaz3140 |
Additional Information | This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science Signaling on Vol. 13 31 March 2020, DOI: 10.1126/scisignal.aaz3140 |
Files
Supplemental material. Low intrinsic efficacy for G protein activation can explain the improved side-effect profile of new opioid agonists
(6.2 Mb)
PDF
Low intrinsic efficacy for G protein activation can explain the improved side-effect profile of new opioid agonists
(2.2 Mb)
PDF
You might also like
Glycosylation Regulates N-Terminal Proteolysis and Activity of the Chemokine CCL14
(2021)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search